What is BioKey?
BioKey operates as a comprehensive CDMO, offering a suite of services that span early-phase product development, analytical services, and clinical supply manufacturing. The company primarily serves clients within the pharmaceutical and nutraceutical sectors. A key differentiator for BioKey is its proprietary oral controlled release technologies, which are instrumental in developing both specialty generic and branded products, including notable offerings like Maitake Mushroom supplements. The company's commitment to quality is evidenced by its cGMP-certified facilities, ensuring adherence to stringent production standards.
How much funding has BioKey raised?
BioKey has raised a total of $132K across 1 funding round:
Debt
$132K
Debt (2021): $132K with participation from PPP
What's next for BioKey?
With the recent strategic investment and a substantial total funding history, BioKey is well-positioned for accelerated growth and innovation. The company's focus on advanced oral controlled release technologies, coupled with its integrated service model, suggests a strategic expansion into more complex pharmaceutical formulations and a broader market reach. Future developments are likely to involve enhancing manufacturing capacity, further refining its proprietary technologies, and potentially forging new partnerships within the pharmaceutical and nutraceutical industries to capitalize on emerging market opportunities. This capital infusion will be critical in supporting BioKey's trajectory towards becoming a leader in specialized drug and supplement manufacturing.
See full BioKey company page
